Bioventus (BVS) Competitors

Bioventus (NASDAQ:BVS) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Which has more risk and volatility, BVS or EYE?

Bioventus has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, National Vision has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Does the media prefer BVS or EYE?

In the previous week, National Vision had 15 more articles in the media than Bioventus. MarketBeat recorded 15 mentions for National Vision and 0 mentions for Bioventus. National Vision's average media sentiment score of 1.20 beat Bioventus' score of 0.00 indicating that National Vision is being referred to more favorably in the news media.

Company	Overall Sentiment
Bioventus	Neutral
National Vision	Positive

Do insiders & institutionals hold more shares of BVS or EYE?

62.9% of Bioventus shares are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Comparatively, 2.7% of National Vision shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate BVS or EYE?

National Vision has a consensus price target of $24.18, suggesting a potential downside of 0.12%. Given National Vision's stronger consensus rating and higher possible upside, analysts clearly believe National Vision is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
National Vision	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

Which has preferable earnings & valuation, BVS or EYE?

National Vision has higher revenue and earnings than Bioventus. National Vision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$573.28M	0.89	-$33.54M	-$0.48	-12.88
National Vision	$1.82B	1.05	-$28.50M	-$0.33	-73.36

Is BVS or EYE more profitable?

National Vision has a net margin of -1.40% compared to Bioventus' net margin of -5.57%. Bioventus' return on equity of 21.47% beat National Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	-5.57%	21.47%	5.38%
National Vision	-1.40%	3.44%	1.40%

Summary

National Vision beats Bioventus on 11 of the 16 factors compared between the two stocks.